Nexviadyme is an enzyme replacement therapy used to treat patients with Pompe disease, a rare inherited disorder caused by the lack of an enzyme called alpha\-glucosidase. Patients with Pompe disease have a build\-up of glycogen (complex sugars) in body tissues, including the heart, lung and skeletal muscles, causing enlarged heart, breathing difficulties and muscle weakness. Nexviadyme contains the active substance avalglucosidase alfa.
Therapeutic Indication
Nexviadyme (avalglucosidase alfa) is indicated for long\-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?\-glucosidase deficiency).
Therapeutic Area (MeSH)
ATC Code
A16
ATC Item
N/A
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| avalglucosidase alfa | N/A | avalglucosidase alfa |
EMA Name
Nexviadyme
Medicine Name
Nexviadyme
Aliases
N/ANo risk management plan link.
